Dolphin Medical Services Launches Open Offer for 26% Stake

Offer Size: 39,25,988 Equity Shares (26% of Voting Capital)
Offer Price: ₹4.80 per share

Reader Takeaway: Open offer provides exit at a premium; note stock's trading restrictions and surveillance status.

What just happened

Dolphin Medical Services Limited has announced a mandatory open offer to acquire 39,25,988 equity shares, representing 26% of its total voting capital. The offer price is set at ₹4.80 per share. This move is triggered by a Share Purchase Agreement (SPA) signed on May 15, 2026, between the proposed acquirers, Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar, and the existing promoters. The objective of this open offer is for the acquirers to gain management control of the company.

The total consideration for the open offer, assuming full acceptance, is approximately ₹1.88 crore. The acquirers have demonstrated sufficient financial capacity, with certified net worths of ₹149.96 crore and ₹3.57 crore, respectively.

Why this matters

This open offer provides an exit route for existing public shareholders at ₹4.80 per share, which is a premium compared to the negotiated SPA price of ₹1.80 per share with the promoters. Investors will need to weigh this premium against the company's recent financial performance and regulatory challenges.

The backstory

Dolphin Medical Services operates in a challenging environment. Its shares have been subject to trading restrictions, limited to Mondays only, due to non-payment of dues. Furthermore, the stock has been under the Enhanced Surveillance Measure (ESM) framework since April 15, 2026. The company has initiated steps to revoke these trading restrictions.

What changes now

If the open offer is fully subscribed, Mr. Amarandhar Reddy Kotha and Mr. Mallour Rajesh Kumar will acquire significant control over Dolphin Medical Services. They intend to continue the company's existing business operations. The offer is scheduled to run from July 09, 2026, to July 22, 2026.

Risks to watch

Investors should carefully consider the company's current trading status, which is restricted to one day a week. The Enhanced Surveillance Measure (ESM) also indicates heightened scrutiny. While the company returned to profitability in FY2026, its revenue saw a slight decrease compared to FY2025.

Peer comparison

Information not available in the provided filing. (Note: Filing did not contain peer comparison data).

Context metrics (time-bound)

• FY 2026 Revenue: ₹0.75 crore (down from ₹0.77 crore in FY 2025)
• FY 2026 Net Profit: ₹0.04 crore (turned profitable from a loss of ₹-0.03 crore in FY 2025)
• FY 2026 Net Worth: ₹10.08 crore
• Open Offer Dates: July 09, 2026 – July 22, 2026
• Trading Suspension Status: Restricted to Mondays, ESM framework active since April 15, 2026.

What to track next

Investors should monitor the subscription level of the open offer and the company's progress in getting its trading restrictions revoked. The company's ability to sustain profitability and improve its operational performance will be key going forward.